Candida glabrata: An emerging pathogen in Brazilian tertiary care hospitals

Medical Mycology

Volumn 51, Issue 1, 2013, Pages 38-44

  Colombo, Arnaldo L ^a   Garnica, Marcia ^b   Aranha Camargo, Luis Fernando ^c   Da Cunha, Clovis Arns ^d   Bandeira, Antonio Carlos ^e   Borghi, Danielle ^f   Campos, Tatiana ^g   Senna, Ana Lucia ^h   Valias Didier, Maria Eugenia ⁱ   Dias, Viviane Carvalho ^d   Nucci, Marcio ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^e Rheumatology Division Centro Médico Do Hospital Aliança   (Brazil)

^f Hospital Copa D'Or   (Brazil)

^g Hospital Barra D'Or   (Brazil)

^h Hospital Quinta D'Or   (Brazil)

ⁱ HOSPITAL FELÍCIO ROCHO   (Brazil)

Author keywords

Candida glabrata; Emergent fungal pathogen; Epidemiology; Fluconazole resistance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; DISEASE SURVEILLANCE; FEMALE; FUNGUS ISOLATION; HOSPITAL INFECTION; HUMAN; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PATHOGENESIS; PICHIA GUILLIERMONDII; PRESCHOOL CHILD; PRIVATE HOSPITAL; PUBLIC HOSPITAL; SCHOOL CHILD; TERTIARY HEALTH CARE;

EID: 84870948401     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.698024     Document Type: Article

References (18)

1. Arnold HM, Micek ST, Shorr AF, et a l. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacother 2010 ; 30: 361-368.
2. Zilberberg MD, Kollef MH, Arnold H, et a l. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect Dis 2010; 10: 150.
3. Colombo AL, Guimaraes T, Silva LRBF, et a l. Prospective observational study of candidemia in Sao Paulo, Brazil: Incidence rate, epidemiology, and predictors of mortality. Infect Cont Hosp Epidemiol 2007 ; 28: 570-576.
4. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010 ; 51: 561-570.
5. Pasqualotto AC, Zimerman RA, Alves SH, et al. Take control over your fl uconazole prescriptions: The growing importance of Candida glabrata as an agent of candidemia in Brazil. Infect Cont Hosp Epidemiol 2008 ; 29: 898-899.
6. Wunsch H, Angus DC, Harrison DA, et a l. Variation in critical care services across North America and Western Europe. Crit Care Med 2008 ; 36: 2787-2793.
7. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard-M27-A3 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
8. Nguyen MH, Clancy CJ, Yu VL, et a l. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998 ; 177: 425-430.
9. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specifi c clinical breakpoints for fl uconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Update 2010 ; 13: 180-195.
10. Colombo AL, Nucci M, Park BJ, et a l. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006 ; 44: 2816-2823.
11. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002 ; 40: 3489-3492.
12. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009 ; 48: 1695-1703.
13. Leroy O, Gangneux JP, Montravers P, et a l. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009 ; 37: 1612-1618.
14. Shaw AB. Age as a basis for healthcare rationingYsupport for agist policies. Drug Aging 1996 ; 9: 403-405.
15. Lloyd-Sherlock P. Population ageing in developed and developing regions: Implications for health policy. Soc Sci Med 2000 ; 51: 887-895.
16. Pfaller MA, Diekema DJ, Gibbs DL, et a l. G eographic variation in the frequency of isolation and fl uconazole and voriconazole susceptibilities of Candida glabrata: An assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010 ; 67: 162-171.
17. Rodriguez D, Almirante B, Cuenca-Estrella M, et al. Predictors of candidaemia caused by non- albicans Candida species: Results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect 2010; 16: 1676-1682.
18. Slavin MA, Sorrell TC, Marriott D, et a l. Candidaemia in adult cancer patients: Risks for fl uconazole-resistant isolates and death. J Antimicrob Chemother 2010 ; 65: 1042-1051.